Last updated on May 2019

A Phase 1 Study of AMG 701 in Subjects With Multiple Myeloma

Brief description of study

The purpose of this First-in-Human Phase 1 study is to determine during the escalation part if AMG 701 given as weekly short term IV infusions is safe and tolerable followed by a dose expansion part to gain further efficacy and safety experience with AMG 701 in adult subjects with relapsed / refractory multiple myeloma. The study will be conducted in multiple sites and test increasing doses of AMG 701. The safety of subjects will be monitored by intensive assessments of vital signs, electrocardiograms, physical examinations, and laboratory tests.

Clinical Study Identifier: NCT03287908

Find a site near you

Start Over

Research Site

Koto-ku, Japan
  Connect »